Pranita D Tamma, M.D., M.P.H.

Headshot of Pranita D Tamma
  • Associate Professor of Pediatrics


Pediatric Infectious Diseases

Research Interests

Diagnosing and treating multidrug-resistant infections; improving antibiotic use among children and adults more


The Johns Hopkins Hospital (Main Entrance)

1800 Orleans St.
Sheikh Zayed Tower
Baltimore, MD 21287
Phone: 410-614-1492
The Johns Hopkins Hospital (Main Entrance) - Google Maps

Johns Hopkins Harriet Lane Clinic

200 N. Wolfe Street
Rubenstein Child Health Building, Suite 3149
Baltimore, MD 21287
Phone: 410-614-3917
Johns Hopkins Harriet Lane Clinic - Google Maps


Pranita Tamma is an Associate Professor of Pediatrics in the Division of Pediatric Infectious Diseases at The Johns Hopkins University School of Medicine. As Medical Director of Antimicrobial Stewardship, she assists clinicians with optimizing the selection of antibiotics to improve patient outcomes while minimizing antibiotic-associated harm. She is the recipient of federal research funding that focuses on improving our understanding of the mechanisms of gram-negative bacterial resistance, improving available diagnostics to identify gram-negative resistant pathogens, and optimizing therapeutic choices for infections caused by multidrug-resistant gram-negative organisms, including novel therapies like phage therapy. more


  • Associate Professor of Pediatrics

Departments / Divisions



  • MD; SUNY Downstate Medical Center (2004)


  • Pediatrics; Johns Hopkins University School of Medicine (2007)


  • Pediatric Infectious Diseases; Johns Hopkins University School of Medicine (2011)

Board Certifications

  • American Board of Pediatrics (Pediatric Infectious Diseases) (2011)

Research & Publications

Selected Publications

View all on PubMed

Simner PJ. Bergman Y, Conzemius R, Jacobs E, Tekle T, Beisken S, Tamma PD. An NDM-Producing Escherichia coli Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Towards Pan-β-Lactam Resistance. Open Forum Infect Dis. 2023 

Tamma PD, Souli M, Billard M, Campbell J, Conrad D, Ellison DW, Evans B, Evans SR, Greenwood-Quaintance KE, Filippov AF, Geres HS, Hamasaki T, Komarow L, Nikolich MP, Lodise TP, Nayak SU, Norice- Tra C, Patel R, Pride D, Russell J, Van Tyne D, Chambers HF, Fowler VG, Schooley RT. Safety and    Microbiological Activity of Phage Therapy in Persons with Cystic Fibrosis Colonized with Pseudomonas aeruginosa: Study Protocol for a Phase 1b/2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Trials. 2022;23(1):1057

Simner PJ, Mostafa HH, Bergman Y, Ante M, Tekle T, Adebayo A, Beisken S, Dzintars K, Tamma PD. Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy Is Associated with Increased blaNDM-5 Copy Number and Gene Expression. Clin Infect Dis. 2022;75(1):47-54.

Amoah J, Klein EY, Chiotos K, Cosgrove SE, *Tamma PD. Administration of a β-lactam Prior to Vancomycin as the First Dose of Antibiotic Therapy Improves Survival in Patients with Bloodstream Infections. Clin Infect Dis. 2022;75(1):98-104

Tamma PD, Beisken S, Bergman Y, Posch AE, Avdic E, Sharara S, Cosgrove SE, Simner PJ. Modifiable Risk Factors for the Emergence of Ceftolozane-Tazobactam Resistance. Clin Infect Dis. 2021;73(11):e4599-e4606.

Activities & Honors


  • National Gale and Ira Drukier Prize in Children’s Health Research, Weill Cornell Medicine


  • Society for Healthcare Epidemiology of America, 2009
  • The Pediatric Infectious Diseases Society, 2008
  • Infectious Diseases Society of America, 2008
Is this you? Edit Profile
back to top button